Christopher Ogden - 15 Jun 2026 Form 4 Insider Report for CytomX Therapeutics, Inc. (CTMX)

Reporting relationship: Chief Financial Officer
Issuer ticker: CTMX
Reported as of: 15 Jun 2026
Net transaction value: -$4,953
SEC form: 4
Accepted by SEC: 17 Jun 2026, 18:38:53 UTC
Prior SEC filing: 19 Mar 2026
Source filing: View source filing
Reporting owner signature: /s/ Christopher Ogden

Key filing fact

Christopher Ogden filed Form 4 for CytomX Therapeutics, Inc. (CTMX) on 17 Jun 2026.

Key facts

This page summarizes Christopher Ogden's Form 4 filing for CytomX Therapeutics, Inc. (CTMX).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 17 Jun 2026, 18:38.

Change

Previous filing in this sequence was filed on 19 Mar 2026.
Current net transaction value: -$4,953.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001914523 Primary reporting owner

Ogden Christopher

Relationship: Chief Financial Officer
Address: C/O CYTOMX THERAPEUTICS, INC., 151 OYSTER POINT BLVD., SUITE 400, SOUTH SAN FRANCISCO
Signature: /s/ Christopher Ogden
Signature date: 17 Jun 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CTMX transaction

Common Stock

Sale

Transaction value: $4,953
Shares: -1,624
Change %: -0.55%
Price: $3.05
Shares after: 295,324
Date: 15 Jun 2026
Ownership: Direct
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of restricted stock units ("RSUs").

Footnote F2

Includes 167,249 RSUs.